ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

trastuzumab deruxtecan

Also written as “Trastuzumab deruxtecan”, “Trastuzumab Deruxtecan” and “DS-8201a”.

Its studies are mostly in Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms · Neoplasm Metastasis · Endometrial Neoplasms, led by 4 companies.

Drug pageTrastuzumab deruxtecan: every studyAll 120 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Apr 13, 201849 company-led studies, 31 open or runningNext primary completion: Feb 10, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Daiichi Sankyoits history only2611 open or runningphase 3since Apr 13, 2018Sep 21, 2015Oct 1, 2027phase 3 · NCT05950945
AstraZenecaits history only2120 open or runningphase 4since May 21, 2024Sep 22, 2017Feb 10, 2027phase 2 · NCT06271837
Pfizer10 open or runningphase 2since Aug 31, 2020Aug 31, 2020none ahead
Strata Oncologyits history only10 open or runningphase 2since Oct 1, 2021Oct 1, 2021none ahead

Also a collaborator on its studies: Parexel, Merck, Bristol-Myers Squibb and Gilead Sciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Pfizer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2016Named trastuzumab deruxtecanINNProposed as its International Nonproprietary Name in WHO's List 116
  2. Aug 31, 2020First study: phase 2 study in Breast NeoplasmsFirst studyNCT04539938 · 70 enrolled · United States

TargetBeta

ERBB2 →read by rule
“An antibody-drug conjugate (ADC) composed of trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (ERBB2; EGFR2; HER2) ”NCIt, by rule
“Receptor protein-tyrosine kinase erbB-2 binding agent”ChEMBL 37, by rule

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
pertuzumabruleHoffmann-La Rochephase 456
tucatinibrulePfizerphase 425
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312
anbenitamabCSPC Pharmaceutical Groupphase 312

Studies

The one study Pfizer leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04539938Breast Neoplasms · United States2CompletedJul 15, 202470

How it is read

Names in the registry

  • “Trastuzumab deruxtecan”, 22 entries
  • “Trastuzumab Deruxtecan”, 10 entries
  • “DS-8201a”, 7 entries
  • “Trastuzumab deruxtecan (DS-8201a)”, 3 entries
  • “T-DXd”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.